Featured Speakers

• 

  Katherine VousdenSenior Scientist - Antibody Discovery and Protein Engineering MedImmune

• 

  Dr Werner MeierVice President, Biologics Drug Discovery Biogen Idec

• 

  Bjoern HockGlobal Head, Protein Engineering & Antibody Technologies Merck Serono

• 

  René HoetVice President, Global Biologics Bayer Healthcare AG

Uncovering the best approaches in optimising antibody characteristics is crucial in producing antibody drugs with blockbuster potential.

Everyone recognises the blockbuster potential of antibody therapies but only a few candidates have successfully realized this value. With so many companies working on just a handful of targets, achieving differentiation is key and novel engineering strategies are a crucial factor for success.  

Overcoming the challenge of developing more stable, more efficacious antibodies with reduced immunogenicity is critical to realise the potential of your pipeline and to enable product superiority.  And with the recent exponential increase of interest in alternative formats, multivalent antibodies and bispecifics, there is now an unrivalled opportunity to apply that knowledge and know-how to develop truly potent antibody therapies.   

Following on from the success of our previous meetings, 5^th Antibody Generation, Engineering and Design will once again bring together the perfect blend of industry experts, innovative technology developers and expert scientists to share experiences and solutions.

It will provide you with an exclusive opportunity to meet, learn, network and debate with leaders of the field from some of the world’s largest drug companies. Distinct from any big biologics meeting where topics range from discovery to market, this industry gathering will be solely focussing on the cutting-edge approaches designed to enhance therapeutic antibody potential.

What’s covered on the agenda?

• Learn how MedImmune are identifying the best possible epitopes and their important role in determining optimal pharmacology 
• Hear from UCB on generating de-risked engineered antibodies through sampling of the immune repertoire
• Novartis reveal how to select the most promising biotherapeutic antibody candidate and increase your chance of commercial success
• Improve your antibody discovery and optimisation with an update on innovative strategies from Bayer,  Pfizer, Genmab and Roche
• Hear the latest engineering case studies from industry, including how Biogen Idec are using their integrated approach to identify therapeutically useful antibody candidates
• Discover how to rapidly select multiple high quality lead candidates with Abbott’s know- how
• Gain a better understanding of structural characteristics to enhance antibody therapeutics with views from  Biogen Idec, Pfizer, MedImmune and Pierre Fabre 

Why attend?

Antibody Generation, Engineering and Design is completed focused on delivering practical value to your antibody drug development programs. With speakers from leaders in the industry covering case studies and speaking openly on solutions to current problems, you’ll leave this meeting fully equipped with ideas on how to improve your own research. 

Click here to see the full speaker line up

Meet innovative scientists and research leaders from the world’s most prominent pharmaceuticals, and understand how they are achieving product differentiation and creating superior antibody drugs with blockbuster potential.

What Next?

1.  Download the agenda to see more detail on the topics for coverage.

2. Stay updated by joining the LinkedIn community. Search groups for “Antibody Engineering and Design”

3. Something you want to share; white papers or articles? Then let us know... just email any questions to info@hansonwade.com

4. Don't waste time! If you're planning on joining us then get the best rates by securing your place now - Book online or call +1 212 537 5898.